Retatrutide Long-Term Side Effects: Trial Data

Retatrutide long-term side effects are not yet fully established, as this investigational triple hormone receptor agonist (GLP-1, GIP and glucagon) holds no marketing authorisation in the UK or elsewhere and has been studied only within clinical trials. Data from Phase 2 and Phase 3 programmes indicate that gastrointestinal effects such as nausea, vomiting and diarrhoea are the most commonly reported adverse events. Several areas of longer-term uncertainty, including cardiovascular outcomes, thyroid safety and muscle mass preservation, remain under active investigation. This article summarises what current trial evidence shows and where significant gaps remain.

What is retatrutide and what is its current status in the UK?

Retatrutide is an investigational triple GLP-1, GIP and glucagon receptor agonist with no UK marketing authorisation; it can only be accessed within an authorised clinical trial and has not been reviewed by NICE or the MHRA for approval.

Retatrutide is an investigational medicine with no marketing authorisation in the UK or anywhere else, meaning it can be accessed only within an authorised clinical trial.^[6][7] It is a triple hormone receptor agonist, acting simultaneously on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This triple mechanism distinguishes it pharmacologically from currently authorised GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro), though no head-to-head trials have been conducted and no direct comparisons can be drawn.

Because retatrutide holds no UK marketing authorisation, it cannot be advertised, and no launch date or regulatory timeline can be given. The MHRA has not authorised it, NICE has not reviewed it, and no Integrated Care Board (ICB) commissioning decision applies to it. Anyone who encounters retatrutide being sold online outside a clinical trial should be aware that such a product would not be a licensed medicine and could be falsified or unsafe. The NHS provides patient-facing information on how clinical trials work and how to find out whether a trial is recruiting.

For people interested in licensed weight-management treatments, options such as tirzepatide (Mounjaro) and semaglutide (Wegovy) are MHRA-authorised and can be discussed with a GP. Retatrutide remains a research medicine, and the safety information available to date comes entirely from clinical trial data, which carries important limitations discussed throughout this article.

What side effects have clinical trials reported so far?

The most commonly reported side effects in retatrutide trials are gastrointestinal, including nausea, vomiting, diarrhoea and constipation, with acute pancreatitis, heart rate increases and gallbladder events also reported.

Clinical trial data for retatrutide, including findings from the Phase 2 programme published in the New England Journal of Medicine and the Phase 3 TRIUMPH and TRANSCEND programmes, indicate that the most commonly reported side effects are gastrointestinal in nature.^[6][7] These include:

• Nausea, which was the most frequently reported adverse event across dose groups^[6][7]

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects are broadly consistent with the class effects seen with other GLP-1 receptor agonists and are generally reported as mild to moderate in severity. They tend to occur more frequently during dose escalation and may diminish over time, though individual responses vary.

Adverse events leading to treatment discontinuation have been reported in trials, with nausea and vomiting among the most common reasons. Injection-site reactions have also been noted. As with other medicines in this class, cases of acute pancreatitis have been reported in trials. The UK SmPCs for authorised medicines in this class, including semaglutide (Wegovy) and tirzepatide (Mounjaro), note that acute pancreatitis has been reported including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, and this signal is being monitored for retatrutide as well.

Heart rate increases have been observed in trial participants, a finding also seen with other GLP-1 receptor agonists and reported in the retatrutide Phase 2 and Phase 3 data. The clinical significance of this in the longer term is not yet established. Gallbladder-related events, including cholelithiasis (gallstones), have been reported in retatrutide trials, which is consistent with the known effects of rapid weight loss on bile composition and with class-level warnings in the UK SmPCs for authorised comparators. All figures and frequencies cited here reflect trial populations and conditions, not general clinical use.

If you are taking part in a clinical trial and experience a suspected side effect, you should report it to the trial team as set out in your study protocol. The MHRA Yellow Card scheme also accepts reports of suspected side effects from clinical trial participants and can be accessed at yellowcard.mhra.gov.uk.

Are there any long-term safety risks we don't yet know about?

Long-term cardiovascular outcomes, thyroid C-cell safety and the effects on muscle mass are not yet established, as retatrutide has only been studied in trials of defined, relatively short duration.

The long-term safety profile of retatrutide is not yet established, because the medicine has not been authorised and has only been studied in clinical trials of defined, relatively short duration. Several areas of uncertainty remain under active investigation.

Cardiovascular outcomes are a key unknown. Authorised GLP-1 receptor agonists have demonstrated cardiovascular benefit in dedicated outcome trials, but no equivalent long-term cardiovascular outcomes trial for retatrutide has reported results.^[14][15] The heart rate increases observed in trials require further characterisation over longer follow-up periods.

Thyroid C-cell findings observed in rodent studies with GLP-1 receptor agonists are a class consideration. The human relevance of these animal findings is uncertain. The UK SmPCs for authorised medicines in this class, including semaglutide (Wegovy) and tirzepatide (Mounjaro), advise that patients should be counselled on the symptoms of thyroid tumours, such as a neck lump, difficulty swallowing or persistent hoarseness. Those same SmPCs state that routine calcitonin testing or thyroid function monitoring is not recommended for this class. Whether equivalent precautionary advice would apply to retatrutide is extrapolated from class labelling; any product-specific guidance would depend on a future SmPC if authorisation were granted.

Muscle mass preservation during significant weight loss is another area of ongoing study. Rapid weight reduction can be associated with loss of lean body mass, and the long-term implications of this with retatrutide's glucagon receptor activity are not yet fully understood.

Because retatrutide is not authorised, suspected adverse events in trial participants are reported to the trial team under the study protocol, as noted in the previous section.

Who may be at greater risk of serious side effects?

People with a history of pancreatitis, gallbladder disease, diabetic retinopathy, severe gastrointestinal conditions or significant comorbidities may face higher risk based on trial data and class pharmacology.

Certain groups of people may face a higher risk of adverse effects based on what is known from retatrutide trials and from the broader pharmacology of the GLP-1 and glucagon receptor agonist class.

People with a history of pancreatitis are a group of particular clinical concern. Acute pancreatitis has been reported with medicines in this class, and individuals with prior episodes of pancreatitis, gallstones or significant alcohol use may warrant closer monitoring. Anyone experiencing severe and persistent abdominal pain, particularly if it radiates to the back, should contact their GP promptly. If symptoms are severe and accompanied by vomiting or collapse, they should call 999 or attend A&E. If you are in a clinical trial, tell the emergency clinician that you are a trial participant and show your study contact card; you should also contact the trial team as soon as possible in line with your study protocol.

People with pre-existing gallbladder disease may be at increased risk of gallstone-related complications, given that rapid weight loss is an established risk factor for cholelithiasis. This is reflected in the UK SmPCs for authorised comparators in this class.

People with pre-existing diabetic eye disease should be aware that rapid improvement in blood glucose control has been associated with transient worsening of pre-existing pre-proliferative or proliferative diabetic retinopathy in trials of related medicines. This is a recognised class consideration, reflected in the UK SmPCs for authorised comparators, and should be discussed with a clinician before entering any trial.

People with severe pre-existing gastrointestinal conditions, such as gastroparesis or other significant motility disorders, are typically excluded from or subject to additional caution in trials of GLP-1-based therapies.^[22] Specific eligibility criteria vary by trial protocol; the relevant trial registration entries set out the inclusion and exclusion criteria that apply.

People of childbearing potential should be aware that trial participants are typically excluded if they are pregnant, breastfeeding or planning pregnancy, in line with the inclusion and exclusion criteria applied across trials of this class. Contraception requirements apply within the trial protocol, and the implications for fertility and pregnancy are not yet established from long-term data.

Older adults and those with renal or hepatic impairment may have altered drug handling, and trial data in these subgroups remain limited. Anyone with significant comorbidities should discuss their individual risk profile with their clinical team before considering trial participation.

What are the limits of the current trial evidence?

Trial duration, selected populations, absence of head-to-head comparisons and no post-marketing data mean the long-term safety profile of retatrutide remains incomplete and should be interpreted cautiously.

The evidence base for retatrutide long-term side effects is subject to several important limitations that readers and clinicians should understand when interpreting published findings.

Trial duration is the most fundamental constraint. Phase 2 and Phase 3 trial periods, while sufficient to detect common adverse events, are not long enough to identify rare events, delayed-onset conditions or effects that emerge only after years of continuous use. The safety profile of any medicine typically becomes more complete after large-scale, long-term post-marketing surveillance, which cannot begin until authorisation is granted.

Trial populations are selected. Participants in clinical trials are screened to exclude people with certain comorbidities, and they receive closer monitoring than would occur in routine clinical practice. This means that adverse event rates observed in trials may not reflect what would be seen in a broader, more heterogeneous population.

Comparator limitations are also relevant. Because no head-to-head trials comparing retatrutide with authorised medicines have been conducted, it is not possible to draw conclusions about whether its side effect profile is better or worse than existing treatments. Trial designs, populations and follow-up periods differ, making cross-trial comparisons unreliable.

Reporting bias within trials means that less common or subjective adverse events may be under-reported, particularly those that participants do not associate with the study medicine.

Finally, because retatrutide has no UK marketing authorisation, there is no post-marketing pharmacovigilance data, no real-world evidence and no NICE technology appraisal. The evidence available today reflects a research medicine at a specific point in its development. Conclusions about its long-term safety profile should be drawn cautiously and updated as further data from the TRIUMPH and TRANSCEND programmes and other trial readouts are published.

Scientific References

1. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
2. Tirzepatide for managing overweight and obesity (TA1026).
3. First GLP-1 tablet for weight loss approved in the UK.
4. Semaglutide | Drugs | BNF - NICE.
5. MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults.
6. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
7. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (PubMed record).
8. Retatrutide in adults with obesity and type 2 diabetes.
9. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.
10. Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opinion on Investigational Drugs.
11. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
12. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
13. Tirzepatide | Drugs | BNF - NICE.
14. Semaglutide and cardiovascular outcomes in patients with overweight or obesity.
15. Comparative Cardiovascular Outcomes and Safety Profiles of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Trials. Cureus.
16. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. Toxicologic Pathology.
17. Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man. Journal of Molecular Endocrinology.
18. Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys. Endocrinology.
19. NG242 Diabetic retinopathy: management and monitoring — effectiveness of intensive treatments to lower blood glucose levels.
20. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity & Metabolism.
21. Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes. Journal of Diabetes and its Complications.
22. GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation.
23. Clinical trials.

Frequently Asked Questions